130 related articles for article (PubMed ID: 26628678)
21. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
Wald DS; Law M; Morris JK; Bestwick JP; Wald NJ
Am J Med; 2009 Mar; 122(3):290-300. PubMed ID: 19272490
[TBL] [Abstract][Full Text] [Related]
22. The effect of vasodilator β-blockers on renal function in hypertensive patients.
Kwon LH; Wats K; Rosendorff C
J Hypertens; 2017 Sep; 35(9):1768-1777. PubMed ID: 28650912
[TBL] [Abstract][Full Text] [Related]
23. The Role of Beta-Blockers in the Treatment of Hypertension.
Cruickshank JM
Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
[TBL] [Abstract][Full Text] [Related]
24. Effects of beta-blockers on glucose and lipid metabolism.
Fonseca VA
Curr Med Res Opin; 2010 Mar; 26(3):615-29. PubMed ID: 20067434
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
Van Bortel LM; Fici F; Mascagni F
Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
[TBL] [Abstract][Full Text] [Related]
26. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials.
Thomopoulos C; Parati G; Zanchetti A
J Hypertens; 2016 Mar; 34(3):373-84; discussion 384. PubMed ID: 26780184
[TBL] [Abstract][Full Text] [Related]
27. Beta-blockers in the treatment of hypertension: are there clinically relevant differences?
Weir MR
Postgrad Med; 2009 May; 121(3):90-8. PubMed ID: 19491545
[TBL] [Abstract][Full Text] [Related]
28. [Modeling of systolic blood pressure reaction to antihypertensive agents in people with hypertension].
Wu Y; Li YS; Bejan-Angoulvant T; Gueyffier F
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Apr; 39(4):309-14. PubMed ID: 21624305
[TBL] [Abstract][Full Text] [Related]
29. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.
Law MR; Wald NJ; Morris JK; Jordan RE
BMJ; 2003 Jun; 326(7404):1427. PubMed ID: 12829555
[TBL] [Abstract][Full Text] [Related]
30. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Lacourcière Y; Neutel JM; Schumacher H
Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
[TBL] [Abstract][Full Text] [Related]
31. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
Schmieder RE; Martus P; Klingbeil A
JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
[TBL] [Abstract][Full Text] [Related]
32. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials.
Messerli FH; Makani H; Benjo A; Romero J; Alviar C; Bangalore S
J Am Coll Cardiol; 2011 Feb; 57(5):590-600. PubMed ID: 21272751
[TBL] [Abstract][Full Text] [Related]
33. Predictors of high central blood pressure in young with isolated systolic hypertension.
Radchenko GD; Torbas OO; Sirenko YM
Vasc Health Risk Manag; 2016; 12():321-8. PubMed ID: 27536127
[TBL] [Abstract][Full Text] [Related]
34. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?
Pedersen ME; Cockcroft JR
Curr Opin Cardiol; 2009 Jul; 24(4):325-32. PubMed ID: 19417638
[TBL] [Abstract][Full Text] [Related]
35. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis.
Bradley HA; Wiysonge CS; Volmink JA; Mayosi BM; Opie LH
J Hypertens; 2006 Nov; 24(11):2131-41. PubMed ID: 17053529
[TBL] [Abstract][Full Text] [Related]
36. Association of cardiovascular events with central systolic blood pressure: A systemic review and meta-analysis.
Li K; Gao L; Jiang Y; Jia J; Li J; Fan F; Zhang Y; Huo Y
J Clin Hypertens (Greenwich); 2024 Jun; ():. PubMed ID: 38884940
[TBL] [Abstract][Full Text] [Related]
37. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
[TBL] [Abstract][Full Text] [Related]
38. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.
Ettehad D; Emdin CA; Kiran A; Anderson SG; Callender T; Emberson J; Chalmers J; Rodgers A; Rahimi K
Lancet; 2016 Mar; 387(10022):957-967. PubMed ID: 26724178
[TBL] [Abstract][Full Text] [Related]
39. Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials.
Peller M; Ozierański K; Balsam P; Grabowski M; Filipiak KJ; Opolski G
Cardiol J; 2015; 22(6):708-16. PubMed ID: 26202651
[TBL] [Abstract][Full Text] [Related]
40. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction.
Takagi H; Mizuno Y; Niwa M; Goto SN; Umemoto T
Hypertens Res; 2014 May; 37(5):432-7. PubMed ID: 24108238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
